Were the August 31, 2026 JAZZ share dispositions open-market sales?

No. The filing states the shares were sold to satisfy tax obligations arising from the vesting of previously granted restricted stock units. This indicates tax-withholding or delivery of shares for taxes, not discretionary open-market selling for investment purposes.

Jazz Pharma director uses 1,706 shares for taxes

Q: What insider transactions did JAZZ director Patrick G. Enright report on August 31, 2026?

He reported two dispositions of ordinary shares on August 31, 2026: 14 shares at $244.64 per share and 1,692 shares at $241.39 per share, all used to satisfy tax obligations from vesting restricted stock units.

Q: How many JAZZ shares did Patrick G. Enright use to cover taxes from RSU vesting?

In total, 1,706 ordinary shares of Jazz Pharmaceuticals were delivered or withheld to cover tax obligations: 14 shares at $244.64 per share and 1,692 shares at $241.39 per share, all tied to the vesting of previously granted restricted stock units.

Q: Was a Rule 10b5-1 trading plan involved in the August 31, 2026 JAZZ transactions?

No. The filing indicates no Rule 10b5-1 trading plan for these transactions. The disposition of 1,706 shares was specifically described as addressing tax obligations from restricted stock unit vesting, rather than trades executed under a pre-arranged trading plan.

Q: What role does Patrick G. Enright hold at Jazz Pharmaceuticals (JAZZ) in this Form 4?

Patrick G. Enright is identified as a director of Jazz Pharmaceuticals plc. The reported August 31, 2026 share dispositions relate to his equity compensation, specifically the vesting of previously granted restricted stock units and associated tax obligations.

A Jazz Pharmaceuticals director used 1,706 shares to cover taxes on vesting restricted stock units, rather than selling shares in the open market.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) director Patrick G. Enright reported two dispositions of ordinary shares on August 31, 2026, when 14 shares at $244.64 and 1,692 shares at $241.39 were delivered or withheld to pay tax obligations arising from the vesting of previously granted restricted stock units; these were not open-market sales and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Tax Withholding: 1,706 shares

Tax Withholding 2 txns

Insider ENRIGHT PATRICK G

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares ^F1	14	$244.6443	$3K
Tax Withholding	Ordinary Shares ^F1	1,692	$241.39	$408K

Holdings After Transaction: Ordinary Shares — 21,278 shares (Direct)

Footnotes (1)

F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Key Figures

Shares delivered or withheld for taxes: 1,706 shares Smaller tax-related disposition: 14 shares at $244.64 per share Larger tax-related disposition: 1,692 shares at $241.39 per share +2 more

5 metrics

Shares delivered or withheld for taxes 1,706 shares Total ordinary shares used to satisfy tax obligations on August 31, 2026

Smaller tax-related disposition 14 shares at $244.64 per share Ordinary shares delivered or withheld on August 31, 2026 to cover tax from RSU vesting

Larger tax-related disposition 1,692 shares at $241.39 per share Ordinary shares delivered or withheld on August 31, 2026 to cover tax from RSU vesting

Number of tax-related transactions 2 transactions Code F dispositions on August 31, 2026 to satisfy tax obligations

Reporting person role Director Position of Patrick G. Enright at Jazz Pharmaceuticals plc

Key Terms

restricted stock units, tax obligations, vesting

3 terms

restricted stock units financial

"vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares sold to satisfy tax obligations arising out of the vesting"

vesting financial

"arising out of the vesting of previously granted restricted stock units"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider transactions did JAZZ director Patrick G. Enright report on August 31, 2026?

He reported two dispositions of ordinary shares on August 31, 2026: 14 shares at $244.64 per share and 1,692 shares at $241.39 per share, all used to satisfy tax obligations from vesting restricted stock units.

How many JAZZ shares did Patrick G. Enright use to cover taxes from RSU vesting?

In total, 1,706 ordinary shares of Jazz Pharmaceuticals were delivered or withheld to cover tax obligations: 14 shares at $244.64 per share and 1,692 shares at $241.39 per share, all tied to the vesting of previously granted restricted stock units.

Was a Rule 10b5-1 trading plan involved in the August 31, 2026 JAZZ transactions?

No. The filing indicates no Rule 10b5-1 trading plan for these transactions. The disposition of 1,706 shares was specifically described as addressing tax obligations from restricted stock unit vesting, rather than trades executed under a pre-arranged trading plan.

What role does Patrick G. Enright hold at Jazz Pharmaceuticals (JAZZ) in this Form 4?

Patrick G. Enright is identified as a director of Jazz Pharmaceuticals plc. The reported August 31, 2026 share dispositions relate to his equity compensation, specifically the vesting of previously granted restricted stock units and associated tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/02/2026 - 05:17 PM Accepted by SEC EDGAR 09/02/2026 - 05:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ENRIGHT PATRICK G

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/31/2026		F⁽¹⁾		14	D	$244.6443	22,970	D
Ordinary Shares	08/31/2026		F⁽¹⁾		1,692	D	$241.39	21,278	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

	By: /s/Paz Dizon, as attorney in fact For: Patrick G. Enright	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR